Radiotherapy for meningiomas.
Anaplastic
Atypical
DOTATATE
Meningioma
Molecular
Radiation
Radiotherapy
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
06
10
2022
accepted:
13
10
2022
pubmed:
1
11
2022
medline:
15
12
2022
entrez:
31
10
2022
Statut:
ppublish
Résumé
Meningiomas are the most common primary central nervous system neoplasm. Despite promising recent progress in elucidating the genomic landscape and underlying biology of these histologically, molecularly, and clinically diverse tumors, the mainstays of meningioma treatment remain maximal safe resection and radiation therapy. The aim of this review of meningioma radiotherapy is to provide a concise summary of the history, current evidence, and future for application of radiotherapy in meningioma treatment.
Identifiants
pubmed: 36315366
doi: 10.1007/s11060-022-04171-9
pii: 10.1007/s11060-022-04171-9
pmc: PMC9722800
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-515Subventions
Organisme : NCI NIH HHS
ID : R01 CA262311
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA151022
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Cushing H, Eisenhardt L (1938) Meningiomas. their classification regional behaviour life history and surgical end results. Hafner. https://doi.org/10.1016/s0002-9610(38)91219-x
doi: 10.1016/s0002-9610(38)91219-x
Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39. https://doi.org/10.1136/jnnp.20.1.22
doi: 10.1136/jnnp.20.1.22
pubmed: 13406590
pmcid: 497230
King DL, Chang CH, Pool JL (1966) Radiotherapy in the management of meningiomas. Acta Radiol 5:26–33. https://doi.org/10.3109/02841856609139540
doi: 10.3109/02841856609139540
Earle KM, Richany SF (1969) Meningiomas. a study of the histology, incidence, and biologic behavior of 243 cases from the Frazier-Grant collection of brain tumors. Med Ann Dist Columbia 38(7):353–6
pubmed: 5255150
Friedman M (1977) Irradiation of meningioma: a prototype circumscribed tumor for planning high-dose irradiation of the brain. Int J Radiat Oncol Biol Phys 2(9–10):949–958. https://doi.org/10.1016/0360-3016(77)90193-6
doi: 10.1016/0360-3016(77)90193-6
pubmed: 591411
Wara WM, Sheline GE, Newman H, Townsend JJ, Boldrey EB (1975) Radiation therapy of meningiomas. Am J Roentgenol 123:453–458. https://doi.org/10.2214/ajr.123.3.453
doi: 10.2214/ajr.123.3.453
Glaholm J, Bloom HJG, Crow JH (1990) The role of radiotherapy in the management of intracranial meningiomas: the royal marsden hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 18(4):755–761. https://doi.org/10.1016/0360-3016(90)90394-y
doi: 10.1016/0360-3016(90)90394-y
pubmed: 2108937
Carella RJ, Ransohoff J, Newall J (1982) Role of radiation therapy in the management of meningioma. Neurosurgery 10:332–339. https://doi.org/10.1227/00006123-198203000-00006
doi: 10.1227/00006123-198203000-00006
pubmed: 7070635
Solan MJ, Kramer S (1985) The role of radiation therapy in the management of intracranial meningiomas. Int J Radiat Oncol Biol Phys 11:675–677. https://doi.org/10.1016/0360-3016(85)90297-4
doi: 10.1016/0360-3016(85)90297-4
pubmed: 3980264
Petty AM, Kun LE, Meyer GA (1985) Radiation therapy for incompletely resected meningiomas. J Neurosurg 62:502–507. https://doi.org/10.3171/jns.1985.62.4.0502
doi: 10.3171/jns.1985.62.4.0502
pubmed: 3973719
Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62(1):18–24. https://doi.org/10.3171/jns.1985.62.1.0018
doi: 10.3171/jns.1985.62.1.0018
pubmed: 3964853
Smith JL, Vuksanovic MM, Yates BM, Bienfang DC (1981) Radiation therapy for primary optic nerve meningiomas. J Clin Neuroophthalmol 1:85–100
pubmed: 6213657
Goldsmith BJ, Wara WM, Wilson CB, Larson DA (1994) Postoperative irradiation for subtotally resected meningiomas a retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80:195–201. https://doi.org/10.3171/jns.1994.80.2.0195
doi: 10.3171/jns.1994.80.2.0195
pubmed: 8283256
Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4
doi: 10.1007/s00401-007-0243-4
pubmed: 17618441
pmcid: 1929165
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropath Exp Neur 61(3):215–225. https://doi.org/10.1093/jnen/61.3.215
doi: 10.1093/jnen/61.3.215
pubmed: 11895036
Rogers CL, Perry A, Pugh S et al (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18(4):565–574. https://doi.org/10.1093/neuonc/nov247
doi: 10.1093/neuonc/nov247
pubmed: 26493095
Rogers L, Barani I, Chamberlain M et al (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties a RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.jns131644
doi: 10.3171/2014.7.jns131644
pubmed: 25343186
pmcid: 5062955
Maclean J, Fersht N, Short S (2014) Controversies in radiotherapy for meningioma. Clin Oncol 26:51–64. https://doi.org/10.1016/j.clon.2013.10.001
doi: 10.1016/j.clon.2013.10.001
Harrison G, Kano H, Lunsford LD, Flickinger JC, Kondziolka D (2016) Quantitative tumor volumetric responses after Gamma Knife radiosurgery for meningiomas. J Neurosurg 124:146–154. https://doi.org/10.3171/2014.12.jns141341
doi: 10.3171/2014.12.jns141341
pubmed: 26162039
Hall JT, Opalak CF, Carr MT, Harris TJ, Broaddus WC (2021) The effect of radiation on meningioma volume change. World Neurosurg 153:e141–e146. https://doi.org/10.1016/j.wneu.2021.06.080
doi: 10.1016/j.wneu.2021.06.080
pubmed: 34166829
Fega KR, Fletcher GP, Waddle MR et al (2019) Analysis of MRI volumetric changes after hypofractionated stereotactic radiation therapy for benign intracranial neoplasms. Adv Radiat Oncol 4:43–49. https://doi.org/10.1016/j.adro.2018.08.013
doi: 10.1016/j.adro.2018.08.013
pubmed: 30706009
de Melo LP, Viani GA, de Paula JS (2021) Radiotherapy for the treatment of optic nerve sheath meningioma: a systematic review and meta-analysis. Radiother Oncol 165:135–141. https://doi.org/10.1016/j.radonc.2021.10.009
doi: 10.1016/j.radonc.2021.10.009
pubmed: 34688809
Leroy HA, Tuleasca C, Reyns N, Levivier M (2018) Radiosurgery and fractionated radiotherapy for cavernous sinus meningioma: a systematic review and meta-analysis. Acta Neurochir 160:2367–2378. https://doi.org/10.1007/s00701-018-3711-9
doi: 10.1007/s00701-018-3711-9
pubmed: 30393820
Rogers L, Pugh S, Vogelbaum M et al (2020) Low-risk meningioma outcomes from NRG Oncology/Rtog 0539. Neuro-Oncol 22:ii55–ii56. https://doi.org/10.1093/neuonc/noaa215.223
doi: 10.1093/neuonc/noaa215.223
pmcid: 7651616
Sheehan J, Pikis S, Islim AI et al (2022) An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study. Neuro Oncol 24:116–124. https://doi.org/10.1093/neuonc/noab132
doi: 10.1093/neuonc/noab132
pubmed: 34106275
Morin O, Chen WC, Nassiri F et al (2019) Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival. Neuro-Oncol Adv. https://doi.org/10.1093/noajnl/vdz011
doi: 10.1093/noajnl/vdz011
Rogers L, Zhang P, Vogelbaum MA et al (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35–47. https://doi.org/10.3171/2016.11.jns161170
doi: 10.3171/2016.11.jns161170
pubmed: 28984517
Weber DC, Ares C, Villa S et al (2018) Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042–26042). Radiother Oncol 128:260–265. https://doi.org/10.1016/j.radonc.2018.06.018
doi: 10.1016/j.radonc.2018.06.018
pubmed: 29960684
Baumgarten P, Gessler F, Schittenhelm J et al (2016) Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol 132:479–481. https://doi.org/10.1007/s00401-016-1598-1
doi: 10.1007/s00401-016-1598-1
pubmed: 27464983
Susko MS, Vasudevan H, Chen WC et al (2020) Patterns of failure after adjuvant radiation for meningioma, radiologic assessment to inform target delineation and treatment planning. Int J Radiat Oncol Biology Phys 108(3):e732–e733. https://doi.org/10.1016/j.ijrobp.2020.07.129
doi: 10.1016/j.ijrobp.2020.07.129
Song D, Xu D, Han H et al (2021) Postoperative adjuvant radiotherapy in atypical meningioma patients: a meta-analysis study. Frontiers Oncol 11:787962. https://doi.org/10.3389/fonc.2021.787962
doi: 10.3389/fonc.2021.787962
Chun SW, Kim KM, Kim MS et al (2021) Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. Radiat Oncol. https://doi.org/10.1186/s13014-021-01759-9
doi: 10.1186/s13014-021-01759-9
pubmed: 34649569
pmcid: 8518257
Keric N, Kalasauskas D, Freyschlag CF et al (2020) Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. J Neuro-oncol 146(2):347–355. https://doi.org/10.1007/s11060-019-03382-x
doi: 10.1007/s11060-019-03382-x
Bray DP, Quillin JW, Press RH et al (2020) Adjuvant radiotherapy versus watchful waiting for world health organization grade II atypical meningioma: a single-institution experience. Neurosurgery 88(5):E435–E442. https://doi.org/10.1093/neuros/nyaa580
doi: 10.1093/neuros/nyaa580
Press RH, Prabhu RS, Appin CL et al (2014) Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 88(5):1004–1010. https://doi.org/10.1016/j.ijrobp.2013.12.037
doi: 10.1016/j.ijrobp.2013.12.037
pubmed: 24661652
Lee JJB, Lee J, Yoon HI et al (2019) Analysis of patterns of failure and appraisal of postoperative radiation field for grade II–III meningioma. J Neurooncol 144:333–341. https://doi.org/10.1007/s11060-019-03232-w
doi: 10.1007/s11060-019-03232-w
pubmed: 31278690
Byun HK, Chang WI, Lee JH et al (2022) Adjuvant radiotherapy versus surveillance for grade 2 intracranial meningiomas: a multi-institutional propensity score-matched study. Frontiers Oncol 12:877244. https://doi.org/10.3389/fonc.2022.877244
doi: 10.3389/fonc.2022.877244
Chen WC, Magill ST, Wu A et al (2019) Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J Neurosurg 130:443–450. https://doi.org/10.3171/2017.9.jns171609
doi: 10.3171/2017.9.jns171609
Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821–1834. https://doi.org/10.1093/neuonc/noab150
doi: 10.1093/neuonc/noab150
pubmed: 34181733
pmcid: 8563316
Nabors LB, Portnow J, Ahluwalia M et al (2020) Central nervous system cancers, version 3.2020. J National Compr Cancer Netw 18:1537–1570. https://doi.org/10.6004/jnccn.2020.0052
doi: 10.6004/jnccn.2020.0052
Dalle CL, Magill ST, Yen AJ et al (2020) Meningioma metastases: Incidence and proposed screening paradigm. J Neurosurg 132:1447–1455. https://doi.org/10.3171/2019.1.jns181771
doi: 10.3171/2019.1.jns181771
Surov A, Gottschling S, Bolz J et al (2013) Distant metastases in meningioma: an underestimated problem. J Neuro-Oncol 112(3):323–327. https://doi.org/10.1007/s11060-013-1074-x
doi: 10.1007/s11060-013-1074-x
Rogers CL, Won M, Vogelbaum MA et al (2020) High-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106:790–799. https://doi.org/10.1016/j.ijrobp.2019.11.028
doi: 10.1016/j.ijrobp.2019.11.028
pubmed: 31786276
Kaur G, Sayegh ET, Larson A et al (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol 16:628–636. https://doi.org/10.1093/neuonc/nou025
doi: 10.1093/neuonc/nou025
pubmed: 24696499
pmcid: 3984561
Press RH, Prabhu RS, Appin CL et al (2014) Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 88:1004–1010. https://doi.org/10.1016/j.ijrobp.2013.12.037
doi: 10.1016/j.ijrobp.2013.12.037
pubmed: 24661652
Attia A, Chan MD, Mott RT et al (2012) Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol 108:179–185. https://doi.org/10.1007/s11060-012-0828-1
doi: 10.1007/s11060-012-0828-1
pubmed: 22359231
pmcid: 3794718
Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS (2012) Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat 11:607–614. https://doi.org/10.7785/tcrt.2012.500267
doi: 10.7785/tcrt.2012.500267
pubmed: 22712601
Pontoriero A, Critelli P, Conti A et al (2022) The “Combo” radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis. J Neuro-Oncol. https://doi.org/10.1007/s11060-022-04107-3
doi: 10.1007/s11060-022-04107-3
Chen WC, Hara J, Magill ST et al (2018) Salvage therapy outcomes for atypical meningioma. J Neurooncol 138:425–433. https://doi.org/10.1007/s11060-018-2813-9
doi: 10.1007/s11060-018-2813-9
pubmed: 29480505
Choudhury A, Magill ST, Eaton CD et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649–659. https://doi.org/10.1038/s41588-022-01061-8
doi: 10.1038/s41588-022-01061-8
pubmed: 35534562
pmcid: 9374001
Boskos C, Feuvret L, Noel G et al (2009) Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys 75:399–406. https://doi.org/10.1016/j.ijrobp.2008.10.053
doi: 10.1016/j.ijrobp.2008.10.053
pubmed: 19203844
Hug EB, DeVries A, Thornton AF et al (2000) Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neuro-Oncol 48(2):151–160. https://doi.org/10.1023/a:1006434124794
doi: 10.1023/a:1006434124794
Prager BC, Vasudevan HN, Dixit D et al (2020) The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies. Cancer Discov 10:1722–1741. https://doi.org/10.1158/2159-8290.cd-20-0160
doi: 10.1158/2159-8290.cd-20-0160
pubmed: 32703768
pmcid: 8194360
Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
doi: 10.1126/science.1233009
pubmed: 23348505
pmcid: 4808587
Clark VE, Harmancl AS, Bai H et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259. https://doi.org/10.1038/ng.3651
doi: 10.1038/ng.3651
pubmed: 27548314
pmcid: 5114141
Harmancl AS, Youngblood MW, Clark VE et al (2017) Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun 8:14433. https://doi.org/10.1038/ncomms14433
doi: 10.1038/ncomms14433
Sahm F, Schrimpf D, Olar A et al (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv377
doi: 10.1093/jnci/djv377
pubmed: 26668184
Shankar GM, Santagata S (2017) BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 19:1447–1456. https://doi.org/10.1093/neuonc/nox094
doi: 10.1093/neuonc/nox094
pubmed: 28482042
pmcid: 5737364
Juratli TA, McCabe D, Nayyar N et al (2018) DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol 136:779–792. https://doi.org/10.1007/s00401-018-1899-7
doi: 10.1007/s00401-018-1899-7
pubmed: 30123936
Sievers P, Hielscher T, Schrimpf D et al (2020) CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140:409–413. https://doi.org/10.1007/s00401-020-02188-w
doi: 10.1007/s00401-020-02188-w
pubmed: 32642869
pmcid: 7423850
Nassiri F, Liu J, Patil V et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597:119–125. https://doi.org/10.1038/s41586-021-03850-3
doi: 10.1038/s41586-021-03850-3
pubmed: 34433969
Driver J, Hoffman SE, Tavakol S et al (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24:796–808. https://doi.org/10.1093/neuonc/noab213
doi: 10.1093/neuonc/noab213
pubmed: 34508644
Youngblood MW, Duran D, Montejo JD et al (2020) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 133:1345–1354. https://doi.org/10.3171/2019.8.jns191266
doi: 10.3171/2019.8.jns191266
Simon M, Kokkino AJ, Warnick RE, Tew JM, von Deimling A, Menon AG (1996) Role of genomic instability in meningioma progression. Genes Chromosom Cancer 16:265–269. https://doi.org/10.1002/(sici)1098-2264(199608)16:4%3c265::aid-gcc7%3e3.0.co;2-w
doi: 10.1002/(sici)1098-2264(199608)16:4<265::aid-gcc7>3.0.co;2-w
pubmed: 8875241
Bi WL, Abedalthagafi M, Horowitz P et al (2016) Genomic landscape of intracranial meningiomas. J Neurosurg 125:525–535. https://doi.org/10.3171/2015.6.jns15591
doi: 10.3171/2015.6.jns15591
pubmed: 26771848
Olar A, Wani KM, Wilson CD et al (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133:431–444. https://doi.org/10.1007/s00401-017-1678-x
doi: 10.1007/s00401-017-1678-x
pubmed: 28130639
pmcid: 5600514
Sahm F, Schrimpf D, Stichel D et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/s1470-2045(17)30155-9
doi: 10.1016/s1470-2045(17)30155-9
pubmed: 28314689
Chen WC, Vasudevan HN, Choudhury A et al (2021) A prognostic gene-expression signature and risk score for meningioma recurrence after resection. Neurosurgery 88:202–210. https://doi.org/10.1093/neuros/nyaa355
doi: 10.1093/neuros/nyaa355
Chen WC, Choudhury A, Vasudevan HN et al (2022) A transcriptomic biomarker for predicting meningioma recurrence. Survival Radiother Response. https://doi.org/10.1055/s-0042-1743637
doi: 10.1055/s-0042-1743637
Patel AJ, Wan YW, Al-Ouran R et al (2019) Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci USA 116:21715–21726. https://doi.org/10.1073/pnas.1912858116
doi: 10.1073/pnas.1912858116
pubmed: 31591222
pmcid: 6815170
Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T (2015) Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol 130:441–443. https://doi.org/10.1007/s00401-015-1459-3
doi: 10.1007/s00401-015-1459-3
pubmed: 26195322
Bashir A, Larsen VA, Ziebell M, Fugleholm K, Law I (2021) Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph PET scanner. Clin Cancer Res 27:2216–2225. https://doi.org/10.1158/1078-0432.ccr-20-3362
doi: 10.1158/1078-0432.ccr-20-3362
pubmed: 33526423
Qi ST, Liu Y, Pan J, Chotai S, Fang LX (2012) A radiopathological classification of dural tail sign of meningiomas. J Neurosurg 117:645–653. https://doi.org/10.3171/2012.6.jns111987
doi: 10.3171/2012.6.jns111987
pubmed: 22839654
Hutzelmann A, Palmié S, Buhl R, Freund M, Heller M (1998) Dural invasion of meningiomas adjacent to the tumor margin on Gd-DTPA-enhanced MR images: histopathologic correlation. Eur Radiol 8:746–748. https://doi.org/10.1007/s003300050466
doi: 10.1007/s003300050466
pubmed: 9601959
Murase M, Tamura R, Kuranari Y et al (2021) Novel histopathological classification of meningiomas based on dural invasion. J Clin Pathol 74:238–243. https://doi.org/10.1136/jclinpath-2020-206592
doi: 10.1136/jclinpath-2020-206592
pubmed: 32546547
Nagashima G, Fujimoto T, Suzuki R, Asai JI, Itokawa H, Noda M (2006) Dural invasion of meningioma: a histological and immunohistochemical study. Brain Tumor Pathol 23:13–17. https://doi.org/10.1007/s10014-006-0193-x
doi: 10.1007/s10014-006-0193-x
pubmed: 18095114
Rokni-Yazdi H, Ardalan FA, Asadzandi Z et al (2009) Pathologic significance of the “dural tail sign.” Eur J Radiol 70:10–16. https://doi.org/10.1016/j.ejrad.2008.01.010
doi: 10.1016/j.ejrad.2008.01.010
pubmed: 18294796
Mahase SS, O’Brien DAR, No D et al (2021) [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neuro-Oncol Adv 3:1–9. https://doi.org/10.1093/noajnl/vdab012
doi: 10.1093/noajnl/vdab012
Perlow HK, Siedow M, Gokun Y et al (2022) 68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys 113(4):859–865. https://doi.org/10.1016/j.ijrobp.2022.04.009
doi: 10.1016/j.ijrobp.2022.04.009
pubmed: 35460804